Sugi Predict

Sugi Predict / Compounds / SCHEMBL863663

SCHEMBL863663

SCHEMBL863663

Brc1ccc2c(c1)CC1(CCNCC1)O2

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HTR2C P28335 3/20 0.46
▸ HDAC3 O15379 4/20 0.41
▸ HDAC4 P56524 4/20 0.41
▸ HDAC1 Q13547 4/20 0.41
▸ HDAC7 Q8WUI4 4/20 0.41
▸ HDAC2 Q92769 4/20 0.41
▸ HDAC10 Q969S8 4/20 0.41
▸ HDAC11 Q96DB2 4/20 0.41
▸ HDAC8 Q9BY41 4/20 0.41
▸ HDAC6 Q9UBN7 4/20 0.41
▸ HDAC9 Q9UKV0 4/20 0.41
▸ HDAC5 Q9UQL6 4/20 0.41
▸ PNMT P11086 1/20 0.38
▸ ASIC3 Q9UHC3 1/20 0.38
▸ OPRD1 P41143 1/20 0.35
▸ AHR P35869 1/20 0.33
▸ HRH3 Q9Y5N1 1/20 0.33
▸ PARP10 Q53GL7 2/20 0.32
▸ TDP2 O95551 1/20 0.32
▸ PARP11 Q9NR21 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL10502567 0.98 HTR2C (0.44) HTR2CHDAC3HDAC4HDAC1HDAC7
SCHEMBL863879 0.94 HDAC3 (0.45) HTR2CHDAC3HDAC4HDAC1HDAC7
SCHEMBL25337824 0.87 HTR2C (0.49) HTR2CHDAC3HDAC4HDAC1HDAC7
SCHEMBL5321592 0.87 HTR2C (0.46) HTR2CHDAC3HDAC4HDAC1HDAC7
SCHEMBL10366330 0.83 KDM4E (0.44) HTR2CAHRLMNAMAPTHTT
SCHEMBL10607243 0.83 KDM4E (0.44) HTR2CAHRLMNAMAPTHTT
Hydrochloric Acid SCHEMBL10502742 0.81 HDAC3 (0.44) HTR2CHDAC3HDAC4HDAC1HDAC7
Hydrochloric Acid SCHEMBL10502741 0.81 HDAC3 (0.44) HTR2CHDAC3HDAC4HDAC1HDAC7
SCHEMBL30172181 0.81 HTR2C (0.49) HTR2CHDAC3HDAC4HDAC1HDAC7
SCHEMBL12569082 0.81 HDAC3 (0.38) HTR2CHDAC3HDAC4HDAC1HDAC7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119462695-A Pyridine derivative and application thereof 康百达（四川）生物医药科技有限公司 2025-02-18 — — CN disclosed
WO-2015069110-A1 MULTIPLE D2 A(NTA)GONISTS/H3 ANTAGONISTS FOR TREATMENT OF CNS-RELATED DISORDERS AAPA B.V. (NL) 2015-05-14 — — WO disclosed
WO-2015069110-A1 MULTIPLE D2 A(NTA)GONISTS/H3 ANTAGONISTS FOR TREATMENT OF CNS-RELATED DISORDERS AAPA B.V. (NL) 2015-05-14 — — WO disclosed
US-20130310389-A1 SUBSTITUTED SPIROCYCLIC PIPERIDINE DERIVATIVES AS HISTAMINE-3 (H3) RECEPTOR LIGANDS CEPHALON, INC. (US) 2013-11-21 — — US disclosed
US-8524713-B2 Substituted spirocyclic piperidine derivatives as histamine-3 (H3) receptor ligands CEPHALON, INC (US) 2013-09-03 — — US disclosed
US-8513232-B2 Substituted spirocyclic piperidine derivatives as histamine-3 (H3) receptor ligands CEPHALON, INC. (US) 2013-08-20 — — US disclosed
EP-2250176-B1 SUBSTITUTED SPIROCYCLIC PIPERIDINE DERIVATIVES AS HISTAMINE-3 (H3) RECEPTOR LIGANDS CEPHALON INC (US) 2012-08-01 — — EP disclosed
US-20120077802-A1 HISTAMINE H3 INVERSE AGONISTS AND ANTAGONISTS AND METHODS OF USE THEREOF SUNOVION PHARMACEUTICALS INC. (US) 2012-03-29 — — US disclosed
US-20120077802-A1 HISTAMINE H3 INVERSE AGONISTS AND ANTAGONISTS AND METHODS OF USE THEREOF SUNOVION PHARMACEUTICALS INC. (US) 2012-03-29 — — US disclosed
US-20120077802-A1 HISTAMINE H3 INVERSE AGONISTS AND ANTAGONISTS AND METHODS OF USE THEREOF SUNOVION PHARMACEUTICALS INC. (US) 2012-03-29 — — US disclosed
EP-2257553-B1 SUBSTITUTED SPIROCYCLIC PIPERIDINE DERIVATIVES AS HISTAMINE-3 (H3) RECEPTOR LIGANDS CEPHALON INC (US) 2011-08-31 — — EP disclosed
US-20110071131-A1 Substituted Spirocyclic Piperidine Derivatives as Histamine-3 (H3) Receptor Ligands CEPHALON, INC. (US) 2011-03-24 — — US disclosed
WO-2010144571-A1 HISTAMINE H3 INVERSE AGONISTS AND ANTAGONISTS AND METHODS OF USE THEREOF SEPRACOR INC. (US) 2010-12-16 — — WO disclosed
EP-2257553-A1 SUBSTITUTED SPIROCYCLIC PIPERIDINE DERIVATIVES AS HISTAMINE-3 (H3) RECEPTOR LIGANDS Cephalon, Inc. (US) 2010-12-08 — — EP disclosed
US-20100298332-A1 Substituted Spirocyclic Piperidine Derivatives as Histamine-3 (H3) Receptor Ligands CEPHALON, INC. (US) 2010-11-25 — — US disclosed
EP-2250176-A1 SUBSTITUTED SPIROCYCLIC PIPERIDINE DERIVATIVES AS HISTAMINE-3 (H3) RECEPTOR LIGANDS Cephalon, Inc. (US) 2010-11-17 — — EP disclosed
WO-2009097309-A1 SUBSTITUTED SPIROCYCLIC PIPERIDINE DERIVATIVES AS HISTAMINE-3 (H3) RECEPTOR LIGANDS CEPHALON, INC. (US) 2009-08-06 — — WO disclosed
WO-2009097567-A1 SUBSTITUTED SPIROCYCLIC PIPERIDINE DERIVATIVES AS HISTAMINE-3 (H3) RECEPTOR LIGANDS CEPHALON, INC. (US) 2009-08-06 — — WO disclosed
US-4420485-A HYPOTENSIVE AGENTS HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) 1983-12-13 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110071131-A1 Substituted Spirocyclic Piperidine Derivatives as Histamine-3 (H3) Receptor Ligands HRH3, HRH4, HRH2 HTR2C 106/4885HDAC3 257/4885HDAC4 488/4885
US-20100298332-A1 Substituted Spirocyclic Piperidine Derivatives as Histamine-3 (H3) Receptor Ligands HRH3, HRH4, HRH2 HTR2C 106/4885HDAC3 257/4885HDAC4 488/4885
US-20130310389-A1 SUBSTITUTED SPIROCYCLIC PIPERIDINE DERIVATIVES AS HISTAMINE-3 (H3) RECEPTOR LIGANDS HRH3, HRH4, HRH2 HTR2C 14/4885HDAC3 258/4885HDAC4 298/4885
US-20120077802-A1 HISTAMINE H3 INVERSE AGONISTS AND ANTAGONISTS AND METHODS OF USE THEREOF HRH3, HRH4, HRH2 HTR2C 133/4885HDAC3 637/4885HDAC4 807/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.